ロード中...
RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB
BACKGROUND: Ependymoma is a rare tumor for which the role of chemotherapy has not been established either for newly diagnosed or recurrent disease. We report on the first prospective adult clinical trial of chemotherapy for recurrent ependymoma. METHODS: Adult (> 18 years) were treated with dose-...
保存先:
| 出版年: | Neuro Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217700/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.998 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|